

## СОБЛЮДЕНИЕ ЭТИЧЕСКИХ СТАНДАРТОВ

Все процедуры, выполненные в исследованиях с участием людей, соответствовали этическим стандартам, утвержденным правовыми актами РФ, принципам Базельской декларации и рекомендациям Локального этического комитета Института экспериментальной медицины (выписка из протокола № 3/19 от 25.04.2019 г.).

## КОНФЛИКТ ИНТЕРЕСОВ

Авторы заявляют об отсутствии конфликта интересов.

## СПИСОК ЛИТЕРАТУРЫ

- Антимонова О.И., Грудинина Н.А., Поляков Д.С., Шавловский М.М. 2016. Белок слияния амилина человека с зеленым флуоресцентным белком "Superfolder." Естественные и мат. науки в совр. мире. Т. 4. № 39. С. 15. (Antimonova O.I., Grudinina N.A., Polyakov D.S., Shavlovskij M.M. 2016. Belok sliyaniya amilina cheloveka s zelenym fluoresentnym belkom "Superfolder." Estestvennye i mat. nauki v sovremennom. mire. V. 4. № 39. P. 15.)
- Сахабеев Р.Г., Поляков Д.С., Гошина А.Д., Вишня А.А., Кудрявцев И.В., Сеницына Е.С., Коржиков-Влах В.А., Теникова Т.Б., Шавловский М.М. 2021. Усиление специфического Т-клеточного иммунного ответа при иммобилизации антигена на микро- и наночастицах. Инфекция и иммунитет. Т. 11. № 4. С. 777. (Sakhabeev R.G., Polyakov D.S., Goshina A.D., Vishnya A.A., Kudryavtsev I.V., Sinitcina E.S., Korzhikov-Vlakh V.A., Tennikova T.B., Shavlovsky M.M. 2021. Enhancing the specific T cell immune response against micro- and nanoparticle immobilized antigen. Russ. J. Infection Immunity. V. 11. № 4. P. 777.) <https://doi.org/10.15789/2220-7619-ETS-1374>
- Begines B., Ortiz T., Pérez-Aranda M., Martínez G., Merinero M., Argüelles-Arias F., Alcludia A. 2020. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials. V. 10. P. 1403.
- Bhattacharya S., Naveena Lavanya Latha J., Kumresan R., Singh S. 2007. Cloning and expression of human islet amyloid polypeptide in cultured cells. Biochem. and Biophys. Res. Commun. V. 356. P. 622.
- Chen M., Rosenberg J., Cai X., Lee A.C.H., Shi J., Nguyen M., Wignakumar T., Mirle V., Edobor A.J., Fung J., Donington J.S., Shanmugarajah K., Lin Y., Chang E. et al. 2021. Nanotraps for the containment and clearance of SARS-CoV-2. Matter. V. 4. P. 2059.
- Davies J.Q., Gordon S. Isolation and culture of human macrophages. Basic Cell Culture Protocols. V. 290. P. 105.
- Fajardo-Moser M., Berzel S., Moll H. 2008. Mechanisms of dendritic cell-based vaccination against infection. Internat. J. Med. Microbiol. V. 298. P. 11.
- Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., Plebanski M. 2004. Vaccines that facilitate antigen entry into dendritic cells. Imm. Cell Biol. V. 82. P. 506.
- Korzhikov-Vlakh V., Averianov I., Sinitsyna E., Nashchekina Y., Polyakov D., Guryanov I., Lavrentieva A., Raddatz L., Korzhikova-Vlakh E., Scheper T., Tennikova T. 2018. Novel pathway for efficient covalent modification of polyester materials of different design to prepare biomimetic surfaces. Polymers. V. 10. P. 1299.
- Lin C.-Y., Lin S.-J., Yang Y.-C., Wang D.-Y., Cheng H.-F., Yeh M.-K. 2015. Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases. Human Vaccines Immunother. V. 11. P. 650.
- Pedelaq J.-D., Cabantous S. 2019. Development and applications of superfolder and split fluorescent protein detection systems in biology. Internat. J. Mol. Sci. V. 20. P. 3479.
- Peres C., Matos A.I., Connot J., Sainz V., Zupančič E., Silva J.M., Graca L., Gaspar R.S., Preat V., Florindo H.F. 2017. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomaterialia. V. 48. P. 41.
- Simón-Vázquez R., Peleteiro M., González-Fernández Á. 2020. Polymeric nanostructure vaccines: applications and challenges. Expert Opinion Drug Delivery. V. 17. P. 1007.
- Taylor P.C., Adams A.C., Hufford M.M., de la Torre I., Winthrop K., Gottlieb R.L. 2021. Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Rev. Immunol. V. 21. P. 382.
- Tyler B., Gullotti D., Mangraviti A., Utsuki T., Brem H. 2016. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Advanced Drug Delivery Rev. V. 107. P. 163.
- Vilos C., Velasquez L.A. 2012. Therapeutic strategies based on polymeric microparticles. J. Biomed. Biotech. V. 2012. P. 1.
- Vlachopoulos A., Karlioti G., Balla E., Daniilidis V., Kalamas T., Stefanidou M., Bikiaris N.D., Christodoulou E., Koumentakou I., Karavas E., Bikiaris D.N. 2022. Poly(lactic acid)-based microparticles for drug delivery applications: an overview of recent advances. Pharmaceutics. V. 14. P. 359.

## Phagocytosis of Protein-Modified Polymer Microparticles by Immune Cells

R. G. Sakhabeev<sup>a, b, \*</sup>, D. S. Polyakov<sup>b</sup>, N. A. Grudinina<sup>b</sup>, O. I. Antimonova<sup>b</sup>, V. A. Korzhikov-Vlakh<sup>c</sup>, E. R. Alikparova<sup>c</sup>, E. S. Sinitsyna<sup>c, d</sup>, and M. M. Shavlovsky<sup>b</sup>

<sup>a</sup>St. Petersburg State Technological Institute (Technical University), St. Petersburg, 190013 Russia

<sup>b</sup>Institute of Experimental Medicine, St.-Petersburg, 197022 Russia

<sup>c</sup>Institute of Chemistry, St.-Petersburg State University, St. Petersburg, 198504 Russia

<sup>d</sup>Institute of Macromolecular Compounds, Russian Academy of Sciences, St. Petersburg, 199004 Russia

\*e-mail: helm505@mail.ru

The ability of three model green proteins to covalently bind to microparticles (MP) based on poly(D,L-lactic acid) (PLA). Green fluorescent protein (sfGFP), recombinant human beta2-microglobulin-sfGFP fusion protein (β2M-sfGFP), and recombinant human amylin-sfGFP fusion protein (IAPP-sfGFP) were isolated by affinity chromatog-

raphy. The double emulsion method was used to form PLA-MPs. The modification of PLA MPs by proteins was testified using laser scanning microscopy (LSM). Phagocytosis of PLA-MPs modified with different proteins and free model proteins by macrophages was also studied using LSM. Recombinant sfGFP has been shown to bind to particle surfaces at lower levels compared to  $\beta$ 2M-sfGFP and IAPP-sfGFP. Presumably, this is due to the fact that amino groups that could potentially react with activated carboxyl groups on particle surfaces, are spatially unavailable for this reaction due to the structure of sfGFP.  $\beta$ 2M and IAPP within the corresponding recombinant proteins are spacer structures between the surface of spherical particles and sfGFP. It was also found that increasing the protein/particle ratio by a factor of three did not lead to an increase in the amount of bound protein per unit mass of particles, which may indicate that the amount of protein that can be bound per unit mass of particles is limited by the capacity of the particles themselves. The study of phagocytosis of PLA-MPs modified with model proteins revealed that MPs bearing  $\beta$ 2M-sfGFP and IAPP-sfGFP were captured by macrophages and, therefore, contribute to the activation of the cellular immune response, which is important in the fight against various viral infections. In addition, model proteins ( $\beta$ 2M-sfGFP, IAPP-sfGFP) appeared to be also capable of phagocytosis. This may be due to the fact that both  $\beta$ 2M and IAPP are amyloidogenic and aggregation prone proteins. Apparently, the aggregates of these proteins are also able to be absorbed by macrophages due to the increase in size compared to their monomeric forms.

**Keywords:** microparticles, poly(lactic acid), protein immobilization, green fluorescent protein, virus “traps”, phagocytosis